drugset / Trial / NCT01841489
A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics
RandomizedCrossoverOpen-labelTreatment
Summary
This is a Phase 1, Open-Label, Adaptive Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics.
Timeline
- Start
- 2013-05
- Primary completion
- 2013-08
- Completion
- 2013-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Entospletinib | Small molecule | 1200 mg | — |
| Subject | Entospletinib | Small molecule | 1600 mg | — |
| Subject | Famotidine | Other / unclassified | 40 mg | — |
| Subject | Omeprazole | Other / unclassified | 20 mg | — |